Replies to post #220962 on Biotech Values

[DewDiligence]

MPH.L acquires OMED in all-stock transaction valued at ~$1.49/sh—a 34% premium to yesterday’s close:

https://finance.yahoo.com/news/proposed-combination-mereo-biopharma-oncomed-131040175.html

…based upon an OncoMed net cash balance of US$38 million at completion, current Mereo shareholders are expected to own approximately 75% of the issued share capital of the Enlarged Group, while current OncoMed shareholders are expected to own approximately 25%...

This deal has aspects of a reverse merger insofar as the impetus for the combination appears to be OMED’s cash balance and Nasdaq listing. The nomianal deal value is $57M, excluding the CVR.